In the early 2000s, kinase specialist and Intellikine Inc. co-founder Kevan Shokat, professor of chemistry and cellular and molecular pharmacology at the University of California, San Francisco, set out to generate a comprehensive panel of selective inhibitors of kinases in the PI3K pathway, including the PI3K isoforms and mTOR.

Their goal was to come up with a set of compounds and scaffolds that could be rationally modified to address the increasingly important kinase space.